Gsa Capital Partners LLP Xeris Biopharma Holdings, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 62,322 shares of XERS stock, worth $454,950. This represents 0.02% of its overall portfolio holdings.
Number of Shares
62,322
Previous 138,735
55.08%
Holding current value
$454,950
Previous $762,000
61.81%
% of portfolio
0.02%
Previous 0.07%
Shares
14 transactions
Others Institutions Holding XERS
# of Institutions
207Shares Held
89.5MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$75.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$71.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$28 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$27.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$26.7 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $992M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...